Clinical Trial Update: A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 first-in-human study is evaluating SB-007 delivered by subretinal injection in Stargardt disease (STGD1), assessing safety, tolerability and prelimi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• SB-007

Snippet

Sponsor: Splice Bio | Conditions: Stargardt Disease, Stargardt Macular Degeneration | Phase 1, Phase 2 | Status: RECRUITING